A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
Clinical trial NCT05813665 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05813665
- Sponsor
- Shanghai JMT-Bio Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-01
- Primary completion
- 2028-06-01
- Enrollment
- 146
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.